Education and Training
A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to determine the safety, pharmacokinetics, and preliminary efficacy information of JNJ-40346527 in patients with relapsed or refractory Hodgkin lymphoma.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Phase 1, Cohort 1
- drug: Phase 1, Cohort 2
- drug: Phase 1, Cohort 3
- drug: Phase 1, Cohort 4
- drug: Phase 2
Eligibility
Inclusion Criteria:
- Patients with histopathologically confirmed initial diagnosis of Hodgkin lymphoma and who
have disease that has relapsed or is refractory that is progressing or active and requires
treatment after at least 1 appropriate therapy
Exclusion Criteria:
- Known brain metastases or leptomeningeal disease
- Other malignancy within past 5 years
- Has any condition that, in the opinion of the investigator, would make study
participation not be in the best interest (eg, compromise the well-being) of the
patient or that could prevent, limit, or confound the protocol-specified assessments
- QTc prolongation at screening or other factors that increase the risk of QT
prolongation such as diagnosis or family history of long-QT syndrome, diagnosed or
suspected congenital long QT syndrome, or concomitant use of medication that can
prolong the QT interval
- Taking CYP3A4 substrate drugs with a narrow therapeutic index (eg, alfentanil,
astemizole, sirolimus, tacrolimus, terfenadine)
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sarah Daadi
650-725-6456
Not Recruiting